---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045896"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:54:19.423185+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted

## Summary
- Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.
- Raised $188M net in April 2025 public offering; pro-forma cash exceeds $624M as of close.
- Q1 2025 net loss of $40.8M ($0.43 loss/share); R&D expense $36.8M, G&A stable at $9.2M.
- Sevasemten Phase 2 LYNX/FOX Duchenne data expected Q2 2025; Part D CIRRUS-HCM data due H2 2025.

## SEC filing metadata
- accession: 0001104659-25-045896
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/0001104659-25-045896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045896
- JSON: https://secwatch.observer/filing/0001104659-25-045896.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.